A Century-Long Public Market Presence Ends as Industry Pressures Mount
Walgreens Boots Alliance (WBA) has sealed a $10 billion deal with private equity firm Sycamore Partners, marking the end of its nearly 100-year run as a publicly traded company. The agreement, which could be worth as much as $23.7 billion, follows months of negotiations and underscores the mounting challenges facing standalone retail pharmacies in an increasingly digital and vertically integrated healthcare landscape.
The announcement, made late Thursday, sent Walgreens shares soaring nearly 7% in premarket trading on Friday. Under the terms of the deal, Walgreens shareholders will receive $11.45 per share in cash, with an additional $3 tied to the future monetization of the company’s debt and equity interest in VillageMD.
The End of an Era
Walgreens’ transition to private ownership marks a significant moment in the retail pharmacy industry. The company first went public in 1927, 26 years after opening its first store in Chicago. However, in recent years, it has struggled to maintain relevance amid the rise of e-commerce, declining prescription reimbursements, and intensifying competition from vertically integrated healthcare giants like CVS Health (CVS).
“While we are making progress against our ambitious turnaround strategy, meaningful value creation will take time, focus, and change that is better managed as a private company,” Walgreens CEO Tim Wentworth stated.
As part of the agreement, Sycamore will take control of all elements of Walgreens’ business, including its specialty pharmacy unit, pharmacy benefit manager (PBM), and its international arm, Alliance Boots. Walgreens’ once-promising VillageMD business is also included in the deal, despite the company previously announcing plans to wind down its stake.
Struggles in a Changing Landscape
Walgreens’ decline reflects broader struggles within the retail pharmacy sector. The company was once valued at over $100 billion in 2015, but its market capitalization has since plummeted to below $10 billion. Although Walgreens reported $147 billion in revenue for fiscal 2024—a 6% year-over-year increase—it also posted a loss per share of $10.
The challenges stem largely from increased competition. Companies like Amazon (AMZN) and digital health platforms such as Hims & Hers (HIMS) have eroded Walgreens’ traditional customer base by offering convenient online pharmacy services. Additionally, grocery chains like Walmart (WMT) and Kroger (KR) have expanded their pharmacy offerings, making it harder for standalone pharmacies to compete.
A Difficult Road Ahead
Industry experts believe Walgreens’ struggles stem from its inability to match the scale and integration of competitors like CVS, which successfully expanded into health insurance and medical services through its Aetna acquisition. Analysts suggest that going private may provide Walgreens the flexibility to restructure and navigate the evolving healthcare market without the constant scrutiny of public investors.
However, the road ahead remains uncertain. Bank of America Securities analyst Allen Lutz noted that Walgreens’ business segments—U.S. Retail Pharmacy, International, and U.S. Healthcare—lack strong synergies. Without a direct relationship with a PBM or health insurer, the company may continue to face structural challenges even under private ownership.
For now, Walgreens’ departure from public markets signals the latest chapter in the retail pharmacy shakeup, as traditional drugstores struggle to adapt to an increasingly digital and vertically integrated healthcare ecosystem.
You might like this article:Macy’s Faces Challenges as Weak Guidance and Tariffs Weigh on Outlook
